From memory the price fell back to these levels when we had the placing back before the summer and then rose back all the way to 15.3 on Eli expectation. There is no reason for it not to do that again. It is hard when you are sitting in negative territory. I had fears the CLN would bring us down and it caused a lot of disagreements amongst long term holders but I stayed because I believed in the science.
B1ll It just seems to be following that pattern from previous. Maybe there are some trades to show and they have been forward sold again. Just wondering as to why we seem to be marched down again.
I know we have more shares coming onto the market, but with 12,000,000 funds, our potential products and possible collaborations I thought we would be worth more at this time.
Was in the 5s last week. I have a feeling another CLN is on the way. I wondered if yesterdays RNS was to keep the share price up. Maybe until CLNs work through this will be the trading range until the powers that be want to take us higher.
When the world starts to move on from Covid being the number one health obsession, not down playing its impact as it has had a terrible effect, people will start realising the effect since its arrival has had on deaths due to cancer and many others and there will be an increased focus on bringing forward treatments for that terrible illness. I wonder then if this will put Hemo back in the spot light with its work toward blood cancer. Especially with improved PR.
RE: RNS - Conversion of Convertible Loan Notes26 Feb 2021 09:15
Aspenwood if I am right there will be multiple CLN applications up until £12000000 paid off. At these levels that's alot of new shares. Please correct me anyone if i am wrong. I know they are limited to how much percentage they can own.
RE: RNS - Conversion of Convertible Loan Notes26 Feb 2021 09:01
Think the price will just be marched down again for the next conversion I am happy to be proved wrong but from experience this is how these financing agreements work just got to hold out and try and reduce averages as more shares hit the market.
And not so long ago people were shot down for suggesting Mint would convert so low. Hemo needed the money and Mint know how to make it. They were not a charity with Hemos best intentions at heart. They are a global business that are there to make money! Got to just let them get through there 12 million CLNs and then move on as we develop our products.
The vaccination programme is working. I have seen a massive reduction in Covid presentation. I don't believe it was to do with lockdown as I feel it hasn't been heavily observed this time round and the Kent variant was far more easily spread and more deadly during the late December early January period. However treatments are still needed and will continue to be for many reasons.I believe in vaccinations and I strongly believe in treatments. That is why I am invested here.
I think he is passionate about the science and the company is means to that final goal. From a business point of view maybe as a shareholder it would be beneficial if the roles were split. Someone who could concentrate on the business and the other on the science. Without one you can not have the other. We brought into Vlad's company and I suppose its his choice.
Shame Vlad didn't do a placing when the price was 10-15 around August time. There was a lot of momentum and interest at that time with the perceived ELI news just around the corner before the extensions to the agreement. Would it have been possible. Any thoughts?